Catalent gains rights to Lyopan fast-dissolve technology
Extends oral dose capabilities
Catalent Pharma Solutions has expanded its oral dose capabilities by signing an agreement with Pantec for the exclusive worldwide development rights to the Swiss development company’s Lyopan fast-dissolve technology.
Lyopan is used in the development and manufacture of fast-dissolve lyophilised tablets, including otc products such as allergy treatments or travel medications.
The technology is said to require significantly less water than existing technology, an advantage that helps reduce energy consumption, sublimation and drying time.
Catalent says the technology offers the potential for improved taste-masking capabilities and may increase the range of drugs and consumer products that can be used in a fast dissolve dosage form.
‘The Lyopan technology is ideally suited to deliver a wide dose range of active pharmaceutical ingredients in a fast-dissolve tablet,’ said Ian Muir, president of Modified Release Technologies at Catalent.
‘These are key considerations for situations where patient adherence, ease of swallowing and lack of access to water are important issues to address.’
The Lyopan technology has clear synergies with several of Catalent’s products, such as Zydis fast dissolve, a freeze-dried oral solid dosage form that disperses instantly in the mouth, without requiring water.